{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-060250","form_type":"8-K","ticker":"OM","cik":"0001484612","company_name":"Outset Medical, Inc.","filed_at":"2023-11-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:29.209490+00:00","generated_at":"2026-06-08T14:39:14.900796+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Outset Medical Q3 revenue $30.4M (+9% YoY); net loss $46.2M; reiterates FY23 guidance ~$130M","bullets":["Revenue $30.4M, +9% YoY; product rev $23.5M (+8.2%), service rev $6.8M (+13.4%).","GAAP gross margin 23.6% (vs 15.6% YoY); non-GAAP 25.6% (vs 16.4% YoY). Service margin dropped to 6.8% from 37%.","Net loss $46.2M ($0.93/share); non-GAAP net loss $35.3M ($0.71/share).","Cash $197M as of Sept 30; operating expenses $52.6M.","Reiterated 2023 revenue guidance ~$130M, gross margin low-20% for year, mid-20% in Q4."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-060250","json":"https://secwatch.observer/filing/0000950170-23-060250.json","markdown":"https://secwatch.observer/filing/0000950170-23-060250.md","text":"https://secwatch.observer/filing/0000950170-23-060250.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1484612/000095017023060250/0000950170-23-060250-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1484612/000095017023060250/om-20231107.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T14:39:14.900796+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"38ddb9d872954a3e37dd6394f10a3c2b136740ef","claim":"Outset Medical, Inc. reported third quarter ended September 30, 2023 results: revenue Revenue for the third quarter was $30.4 million, net income Net loss was ($46.2) million, EPS ($0.93) per share. Guidance reaffirmed.","evidence_excerpt":"technology to reduce the cost and complexity of dialysis, today reported financial results for the third quarter ended September 30, 2023. Revenue for the third quarter was $30.4 million, a 9% increase over revenue of $27.8 million in the third quarter of 2022, and gross margin was 23.6%, or 25.6% on a non-GAAP basis, compared to 16.4% on a non-GAAP basis in the","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1484612/000095017023060250/0000950170-23-060250-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"third quarter ended September 30, 2023"},{"label":"Revenue","value":"Revenue for the third quarter was $30.4 million"},{"label":"Net income","value":"Net loss was ($46.2) million"},{"label":"EPS","value":"($0.93) per share"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}